February 5th 2020
By Allison Inserro
Reference pricing may shift the mix of drugs dispensed from those offering the highest rebates to pharmacy benefit managers to those offering the lowest prices to employers and employees, according to a new study published Wednesday.
January 29th 2020
By Deana Ferreri, PhD
Researchers reviewed randomized controlled trials and real-world evidence studies on nonmedical switching; that is, switching patients who are doing well on their current originator therapy to a biosimilar.
January 18th 2020
The biosimilar CPT-13 (Remsima) is currently approved in Europe for all uses for which the originator infliximab (Remicade) is approved, including Crohn disease (CD) and ulcerative colitis (UC), which are often referred to collectively as IBD.
January 11th 2020
The Center for Biosimilars® recaps the top stories for the week of January 6.
January 10th 2020
By The Center for Biosimilars Staff
It is the first adalimumab biosimilar approved by the China National Medical Products Administration.
January 8th 2020
By Mary Caffrey
Just 6% of the Asian doctors said they felt confident using biosimilars in clinical practice. A survey of European doctors found a similar confidence level in 2013, but that level had climbed to 28.8% by 2015.
January 4th 2020
The findings indicate that interventions that leverage physician relationships may assist with increasing uptake of new, high-value cancer treatments in place of low-value therapies.
January 3rd 2020
By Kelly Davio
Using the biosimilar resulted in a significantly lower drug acquisition cost, at $533.40 in the biosimilar group versus $1261.90 in the reference group.
The Center for Biosimilars® recaps the top stories for the week of December 30, 2019.
January 2nd 2020
The Inflammatory Bowel Disease Net, an official working group of the Swiss Society of Gastroenterology, has issued a new position statement on the use of biosimilars in treating inflammatory bowel disease (IBD).
